Biogen, Inc. - Product Pipeline Review - 2016

  • ID: 3641074
  • Company Profile
  • 94 pages
  • Global Markets Direct
  • Biogen Inc.
1 of 4
Biogen, Inc. - Product Pipeline Review - 2016

Summary

‘Biogen, Inc. - Product Pipeline Review - 2016’, provides an overview of the Biogen, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Biogen, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Biogen, Inc.
- The report provides overview of Biogen, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Biogen, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Biogen, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Biogen, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Biogen, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Biogen, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Biogen, Inc. Snapshot

Biogen, Inc. Overview

Key Information

Key Facts

Biogen, Inc. - Research and Development Overview

Key Therapeutic Areas

Biogen, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Biogen, Inc. - Pipeline Products Glance

Biogen, Inc. - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

Biogen, Inc. - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Biogen, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Biogen, Inc. - Drug Profiles

coagulation factor IX (recombinant), Fc fusion protein

Product Description

Mechanism of Action

R&D Progress

rituximab

Product Description

Mechanism of Action

R&D Progress

aducanumab

Product Description

Mechanism of Action

R&D Progress

amiselimod hydrochloride

Product Description

Mechanism of Action

R&D Progress

BG-00011

Product Description

Mechanism of Action

R&D Progress

natalizumab

Product Description

Mechanism of Action

R&D Progress

opicinumab

Product Description

Mechanism of Action

R&D Progress

raxatrigine hydrochloride

Product Description

Mechanism of Action

R&D Progress

BG-00001

Product Description

Mechanism of Action

R&D Progress

BIIB-054

Product Description

Mechanism of Action

R&D Progress

BIIB-059

Product Description

Mechanism of Action

R&D Progress

BIIB-061

Product Description

Mechanism of Action

R&D Progress

BIIB-063

Product Description

Mechanism of Action

R&D Progress

dapirolizumab pegol

Product Description

Mechanism of Action

R&D Progress

5-D10

Product Description

Mechanism of Action

R&D Progress

CNV-1061436

Product Description

Mechanism of Action

R&D Progress

CNV-3000164

Product Description

Mechanism of Action

R&D Progress

CNV-3000223

Product Description

Mechanism of Action

R&D Progress

Gene Therapy for Hemophilia B

Product Description

Mechanism of Action

R&D Progress

NI-105

Product Description

Mechanism of Action

R&D Progress

NI-205

Product Description

Mechanism of Action

R&D Progress

PRT-2761

Product Description

Mechanism of Action

R&D Progress

Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein to Replace Factor VIII for Hemophilia A

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize GPR-84 for Chronic Pain

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize P2Y14 for Osteoarthritic Pain

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit mPGES-1 for Chronic Pain

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Agonize ROR-Gamma for Autoimmune Disease

Product Description

Mechanism of Action

R&D Progress

Biogen, Inc. - Pipeline Analysis

Biogen, Inc. - Pipeline Products by Target

Biogen, Inc. - Pipeline Products by Route of Administration

Biogen, Inc. - Pipeline Products by Molecule Type

Biogen, Inc. - Pipeline Products by Mechanism of Action

Biogen, Inc. - Recent Pipeline Updates

Biogen, Inc. - Dormant Projects

Biogen, Inc. - Discontinued Pipeline Products

Discontinued Pipeline Product Profiles

baminercept alfa

BG-00010

BIIB-023

clenoliximab

CNF-1010

dexpramipexole dihydrochloride

naxifylline

Biogen, Inc. - Company Statement

Biogen, Inc. - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

Biogen, Inc. - Key Manufacturing Facilities

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Biogen, Inc., Key Information

Biogen, Inc., Key Facts

Biogen, Inc. - Pipeline by Indication, 2016

Biogen, Inc. - Pipeline by Stage of Development, 2016

Biogen, Inc. - Monotherapy Products in Pipeline, 2016

Biogen, Inc. - Partnered Products in Pipeline, 2016

Biogen, Inc. - Partnered Products/ Combination Treatment Modalities, 2016

Biogen, Inc. - Out-Licensed Products in Pipeline, 2016

Biogen, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016

Biogen, Inc. - Pre-Registration, 2016

Biogen, Inc. - Phase III, 2016

Biogen, Inc. - Phase II, 2016

Biogen, Inc. - Phase I, 2016

Biogen, Inc. - Preclinical, 2016

Biogen, Inc. - Discovery, 2016

Biogen, Inc. - Pipeline by Target, 2016

Biogen, Inc. - Pipeline by Route of Administration, 2016

Biogen, Inc. - Pipeline by Molecule Type, 2016

Biogen, Inc. - Pipeline Products by Mechanism of Action, 2016

Biogen, Inc. - Recent Pipeline Updates, 2016

Biogen, Inc. - Dormant Developmental Projects,2016

Biogen, Inc. - Discontinued Pipeline Products, 2016

Biogen, Inc., Other Locations

Biogen, Inc., Subsidiaries

Biogen, Inc., Key Manufacturing Facilities

List of Figures

Biogen, Inc. - Pipeline by Top 10 Indication, 2016

Biogen, Inc. - Pipeline by Stage of Development, 2016

Biogen, Inc. - Monotherapy Products in Pipeline, 2016

Biogen, Inc. - Partnered Products in Pipeline, 2016

Biogen, Inc. - Out-Licensed Products in Pipeline, 2016

Biogen, Inc. - Pipeline by Top 10 Target, 2016

Biogen, Inc. - Pipeline by Route of Administration, 2016

Biogen, Inc. - Pipeline by Molecule Type, 2016

Biogen, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll